BACKGROUND: The association between abacavir (ABC) and cardiovascular disease (CVD) risk in HIV-infected individuals is unclear. Putative mechanisms for an effect of ABC on CVD risk including endothelial dysfunction have been proposed; however, a biological mechanism has not been established. METHODS: This was a cross-sectional study of HIV-infected subjects with HIV RNA levels <400 copies/ml, who were randomly assigned to ABC or tenofovir (TDF) as initial therapy during a prior clinical trial. A small cohort of subjects on zidovudine (AZT; not randomly assigned) were studied to explore long-term exposure to this agent. All underwent brachial artery ultrasound for flow-mediated dilation (FMD), and D-dimer, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and fasting lipids were measured. Between-arm differences were evaluated by multivariable linear or logistic regression modelling. RESULTS: There were 148 subjects (46 on ABC, 72 on TDF and 30 on AZT). Demographic characteristics were balanced across the groups except, as expected, AZT-treated participants were older, had higher CD4(+) T-cell counts, and longer antiretroviral therapy duration. After adjusting for age, brachial artery diameter, and treatment duration, FMD was similar in those on ABC (3.9%) and TDF (5.4%; P=0.181). FMD was higher in those on AZT (6.1%; P<0.005). Levels of IL-6, hsCRP and detectable D-dimer were similar between groups. CONCLUSIONS: Among individuals assigned to ABC or TDF in randomized clinical trials there were no significant differences in FMD or markers of inflammation and coagulation. Whether ABC contributes to risk of CVD remains unclear, but our results suggest that endothelial dysfunction, heightened inflammation, and altered coagulation are unlikely to be mechanisms by which the drug could increase CVD risk above that seen with TDF.
RCT Entities:
BACKGROUND: The association between abacavir (ABC) and cardiovascular disease (CVD) risk in HIV-infected individuals is unclear. Putative mechanisms for an effect of ABC on CVD risk including endothelial dysfunction have been proposed; however, a biological mechanism has not been established. METHODS: This was a cross-sectional study of HIV-infected subjects with HIV RNA levels <400 copies/ml, who were randomly assigned to ABC or tenofovir (TDF) as initial therapy during a prior clinical trial. A small cohort of subjects on zidovudine (AZT; not randomly assigned) were studied to explore long-term exposure to this agent. All underwent brachial artery ultrasound for flow-mediated dilation (FMD), and D-dimer, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and fasting lipids were measured. Between-arm differences were evaluated by multivariable linear or logistic regression modelling. RESULTS: There were 148 subjects (46 on ABC, 72 on TDF and 30 on AZT). Demographic characteristics were balanced across the groups except, as expected, AZT-treated participants were older, had higher CD4(+) T-cell counts, and longer antiretroviral therapy duration. After adjusting for age, brachial artery diameter, and treatment duration, FMD was similar in those on ABC (3.9%) and TDF (5.4%; P=0.181). FMD was higher in those on AZT (6.1%; P<0.005). Levels of IL-6, hsCRP and detectable D-dimer were similar between groups. CONCLUSIONS: Among individuals assigned to ABC or TDF in randomized clinical trials there were no significant differences in FMD or markers of inflammation and coagulation. Whether ABC contributes to risk of CVD remains unclear, but our results suggest that endothelial dysfunction, heightened inflammation, and altered coagulation are unlikely to be mechanisms by which the drug could increase CVD risk above that seen with TDF.
Authors: B Takase; A Uehata; T Akima; T Nagai; T Nishioka; A Hamabe; K Satomura; F Ohsuzu; A Kurita Journal: Am J Cardiol Date: 1998-12-15 Impact factor: 2.778
Authors: Graeme J Moyle; Caroline A Sabin; Jonathan Cartledge; Margaret Johnson; Edmund Wilkins; Duncan Churchill; Philip Hay; Ade Fakoya; Maurice Murphy; George Scullard; Clifford Leen; Geraldine Reilly Journal: AIDS Date: 2006-10-24 Impact factor: 4.177
Authors: Claudette S Satchell; Jane A O'Halloran; Aoife G Cotter; Aaron J Peace; Eileen F O'Connor; Anthony F Tedesco; Eoin R Feeney; John S Lambert; Gerard J Sheehan; Dermot Kenny; Patrick W G Mallon Journal: J Infect Dis Date: 2011-10-15 Impact factor: 5.226
Authors: A Uehata; E H Lieberman; M D Gerhard; T J Anderson; P Ganz; J F Polak; M A Creager; A C Yeung Journal: Vasc Med Date: 1997 Impact factor: 3.239
Authors: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Paul E Sax Journal: AIDS Date: 2012-07-17 Impact factor: 4.177
Authors: Francesca J Torriani; Lauren Komarow; Robert A Parker; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; James H Stein Journal: J Am Coll Cardiol Date: 2008-08-12 Impact factor: 24.094
Authors: R Joannides; W E Haefeli; L Linder; V Richard; E H Bakkali; C Thuillez; T F Lüscher Journal: Circulation Date: 1995-03-01 Impact factor: 29.690
Authors: Guinevere Q Lee; Suzanne McCluskey; Yap Boum; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; Xiaojiang Gao; P Richard Harrigan; Jessica E Haberer; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2017-10-01 Impact factor: 3.731
Authors: A Calcagno; S Nozza; C Muss; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; D Ripamonti; A Riva; G Di Perri Journal: Infection Date: 2015-05-19 Impact factor: 3.553
Authors: Nath Zungsontiporn; Lishomwa C Ndhlovu; Brooks I Mitchell; James H Stein; Kalpana J Kallianpur; Beau Nakamoto; Sheila M Keating; Philip J Norris; Scott A Souza; Cecilia M Shikuma; Dominic C Chow Journal: HIV Clin Trials Date: 2015-11
Authors: Jordan E Lake; Sophie Seang; Theodoros Kelesidis; Diana H Liao; Howard N Hodis; James H Stein; Judith S Currier Journal: HIV Clin Trials Date: 2015-09-11
Authors: James H Stein; Noah Kime; Claudia E Korcarz; Heather Ribaudo; Judith S Currier; Joseph C Delaney Journal: Arterioscler Thromb Vasc Biol Date: 2020-12-17 Impact factor: 8.311
Authors: Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren Journal: BMC Med Date: 2016-03-31 Impact factor: 8.775